Oveporexton for Type 1 Narcolepsy
Narcolepsy UK would like to update our community on a recent draft scope consultation from NICE about the possible evaluation of oveporexton for the treatment of type 1 narcolepsy.
Following careful review, we have submitted a formal response to NICE as part of the consultation process.
Our response reflects the experiences and priorities of people living with narcolepsy, including the challenges of current treatment options and the importance of improving quality of life.
We will continue to monitor developments closely and share further updates as the appraisal progresses.
Narcolepsy UK will continue to advocate for people living with narcolepsy and keep the community updated as developments emerge. Our work is informed by the Narcolepsy UK Charter, shaped by the contributions of so many people in our community. Please consider donating to support this work.
What this means for you
- This is an early step in the process, and oveporexton is not yet available in the UK.
- Narcolepsy UK has represented the voice of the community through its response.
- This may signal progress in the development of future treatment options.
- There are no immediate changes to your care or treatment.
- We will keep you updated as more information becomes available.
FAQ: Oveporexton
What is oveporexton?
Oveporexton is an investigational medicine being developed for people with type 1 narcolepsy.
Is it available?
No. Oveporexton has not yet been approved for use in the UK. The MHRA (Medicines and Healthcare products Regulatory Agency) would need to assess whether it is safe and effective before it could become available. NICE is currently consulting on the draft scope for a possible evaluation, which helps define what any future appraisal would cover.
How is it different from current treatments?
It is being studied as a daily treatment designed to replace signalling that is missing in people with type 1 narcolepsy.
Has it been tested in clinical trials?
Yes. It has been studied in clinical trials, including large Phase 3 studies.
When might it be available?
That will depend on future regulatory decisions by the MHRA and on any subsequent NICE guidance.
Will this change my treatment?
Not There are no changes to your current treatment.
🔗 Further information
- https://www.takeda.com/newsroom/newsreleases/2025/positive-results-phase-3-oveporexton-narcolepsy-type-1/
- https://www.takeda.com/newsroom/newsreleases/2026/fda-accepts-nda-priority-review-oveporexton-narcolepsy-type-1/
Background: Orexin Agonists
What the orexin system does
Orexins (hypocretins) are neuropeptides produced in the hypothalamus that regulate wakefulness, arousal, and sleep–wake stability. This system helps stabilise wakefulness and prevent sudden transitions into sleep. When orexin signalling is lost, sleep–wake cycles become unstable, as seen in narcolepsy.
What orexin agonists are and how they work
Orexin agonists are medicines that bind to and activate orexin receptors (OX1R and/or OX2R). They are designed to mimic natural orexin peptides and restore signalling when it is deficient. Activating these receptors increases neuronal activity and neurotransmitter release, which promotes wakefulness and alertness.
Importance of the OX2 receptor
There are two orexin receptors: OX1R and OX2R. OX2R is the main receptor involved in wakefulness regulation, which is why most medicines in development are OX2R-selective agonists.
Main clinical application: narcolepsy
Narcolepsy type 1 is caused by the loss of orexin-producing neurons. Symptoms include excessive daytime sleepiness and cataplexy. Orexin agonists aim to restore the missing biological signal rather than simply manage symptoms.
Drug development status
Most orexin agonists are still in clinical development. A key example is oveporexton (TAK-861), an advanced-stage investigational medicine. There are currently no widely available approved orexin agonists.
Clinical effects observed so far
Observed effects in studies so far include increased wakefulness and alertness, reduced narcolepsy symptoms, and potential improvements in cognitive function.
Why they are important
They represent a new class of wakefulness therapy that aims to address the underlying orexin deficiency and may support more natural regulation of the sleep–wake cycle.
Key limitations
These medicines are still investigational, long-term safety has not yet been fully established, and development remains challenging.
Overall takeaway
Orexin agonists are designed to replace missing signalling in narcolepsy and differ from current treatments because they aim to address the underlying cause, rather than only manage symptoms.